> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Vote on Converting Paxlovid EUA to Traditional Approval
- URL: https://www.fdaweb.com/panel-to-vote-on-converting-paxlovid-eua-to-traditional-approval/
- Published: 2023-02-24T12:00:00.000Z
- Updated: 2026-09-14T18:17:16.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5153852

A Pfizer NDA to convert its emergency use authorization for Covid-19 drug Paxlovid (nirmatrelvir and ritonavir co-packaged tablets) to a traditional approval is heading to a 3/16 Antimicrobial Drugs Advisory Committee meeting review and vote. The company is seeking an indication for treating mild-to-moderate coronavirus disease (Covid-19) in adults who are at high risk for progression to severe Covid-19, including hospitalization or death.

Paxlovid generated about $19 billion in revenues last year, and it is projected to decline to $8 billion this year as fewer cases of Covid-19 are expected. It is believed that gaining traditional approval for Paxlovid could lead to more use by those reluctant to take therapies that are not “FDA approved.”